Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

German Tamoxifen Shortage Shows Consequences Of Cost Containment

Medicines For Europe Urges Change To ‘Unsustainable’ Procurement Policies

Executive Summary

Supply issues around breast cancer treatment tamoxifen in Germany demonstrate the damaging effects of European cost-containment measures, Medicines for Europe has warned, citing an “urgent need to revise unsustainable pricing and tendering policies.”

You may also be interested in...



Pfizer Warns Against Applying Generic Policies To Biosimilars

Pfizer’s biosimilars commercial lead, Roman Irsiegler, has set out his views on policy obstacles for biosimilars that need to be addressed if the market is to sustainably deliver on its potential.

Medicines For Europe’s Sieger: ‘We Have To Create An Ecosystem Where We Can Compete’

Markus Sieger, vice-president of off-patent industry association Medicines for Europe and CEO of Polpharma, spoke to Generics Bulletin about critical issues affecting supply in Europe, including pricing, supply chains, and his enthusiasm for ESG.

European Industry Voices Concern As Products Vanish From Market

A fresh report has offered stark new data on the extent to which generics are disappearing from the European market. Industry association Medicines for Europe has pointed to the risks of supply consolidation, urging both national- and EU-level action.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB151655

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel